# Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer

Source: https://onco.cc/trials/nct06840704/  
OnCo record `nct06840704` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in lung cancer, run by Hunan Cancer Hospital, now recruiting.

## Summary

Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer is a phase 3, randomised interventional study registered as NCT06840704 by Hunan Cancer Hospital, with a registry enrolment figure of 121 participants, started 2025-02-25 and due to reach its primary completion in 2026-06-30. Interventions recorded: Oral immunonutrition. Conditions listed: Non Small Cell Lung Cancer; Small Cell Lung Cancer. Primary outcome: Incidence rate of grade 2 or higher acute esophagitis. Lung eligibility wording from the registry: "Pathologically confirmed diagnosis of lung cancer, including non-small cell lung cancer and small cell lung cancer". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: Relief
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06840704
- Phase: 3
- Setting: Immunonutrition in Reducing Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer: a Prospective, Randomized, Controlled, Open-label Clinical Trial
- Sponsor: Hunan Cancer Hospital
- Enrolled: 121

## Sources

- ClinicalTrials.gov NCT06840704: https://clinicaltrials.gov/study/NCT06840704

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06840704.json